New Strong Buy Stocks for February 27th
NABZY, DVA, FOR, RUN and ONTO have been added to the Zacks Rank #1 (Strong Buy) List on February 27, 2026.
Here's Why DaVita HealthCare (DVA) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is DaVita (DVA) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why DaVita HealthCare (DVA) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Should Value Investors Buy DaVita (DVA) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DaVita Stock Up Following Q4 Earnings & Revenue Beat, Margins Expand
DVA reports a fourth-quarter 2025 earnings and revenue beat as margins expanded and full-year adjusted EPS rose by double digits.
DaVita Inc. (DVA) Q4 2025 Earnings Call Transcript
DaVita Inc. (DVA) Q4 2025 Earnings Call Transcript
DaVita HealthCare (DVA) Q4 Earnings and Revenues Surpass Estimates
DaVita HealthCare (DVA) came out with quarterly earnings of $3.4 per share, beating the Zacks Consensus Estimate of $3.24 per share. This compares to earnings of $2.24 per share a year ago.
DaVita forecasts 2026 profit above estimates on steady dialysis service demand; shares jump
DaVita projected annual profit above estimates on Monday after reporting better-than-expected fourth-quarter results on steady demand for its kidney dialysis services, sending its shares up 13% in after-hours trading.
Can Operational Execution Support DaVita's Q4 Performance?
DVA's fourth-quarter 2025 performance is likely to have gained from technology upgrades, cost control and seasonal boosts despite ongoing volume headwinds.
DaVita HealthCare (DVA) Stock Falls Amid Market Uptick: What Investors Need to Know
DaVita HealthCare (DVA) concluded the recent trading session at $105.61, signifying a -1.77% move from its prior day's close.
